Lipoxin and aspirin-triggered lipoxins

Area of Science:

• Biochemistry
• Immunology
• Pharmacology

Background:

• Lipoxins and aspirin-triggered lipoxins (ATL) are eicosanoids synthesized via sequential lipoxygenase (LO) metabolism.
• Biosynthesis involves 15-LO/5-LO or 12-LO/5-LO pathways, with ATL generated by 5-LO and aspirin-acetylated COX-2.
• Cellular models include leukocytes, platelets, vascular endothelium, and epithelium.

Purpose of the Study:

• To explore the therapeutic potential of stable lipoxin and ATL analogs.
• To investigate their anti-inflammatory activities in various disease models.
• To understand the role of the FPR2/ALX receptor in lipoxin-mediated signaling.

Main Methods:

• Synthesis of stable lipoxin and ATL analogs.
• Evaluation of anti-inflammatory activity in animal models of diseases.
• Assessment of signaling pathways involving the FPR2/ALX receptor.

Main Results:

• Stable analogs demonstrated potent and long-lasting biological activity.
• Analogs showed significant anti-inflammatory effects in models of reperfusion injury, arthritis, and various organ-specific inflammatory disorders.
• Lipoxin A4 and 15-epi-lipoxin A4 activate the FPR2/ALX receptor, a key anti-inflammatory mediator in myeloid cells.

Conclusions:

• Stable lipoxin and ATL analogs possess significant therapeutic potential for inflammatory diseases.
• The FPR2/ALX receptor is a crucial target for lipoxin-mediated anti-inflammatory effects.
• Further development of these analogs could lead to novel treatments for a wide range of inflammatory conditions.